These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27092905)

  • 1. Safety considerations in providing allergen immunotherapy in the office.
    Mattos JL; Lee S
    Curr Opin Otolaryngol Head Neck Surg; 2016 Jun; 24(3):226-30. PubMed ID: 27092905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining quality metrics and improving safety and outcome in allergy care.
    Lee S; Stachler RJ; Ferguson BJ
    Int Forum Allergy Rhinol; 2014 Apr; 4(4):284-91. PubMed ID: 24449697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of quality improvement measures on the delivery of allergy immunotherapy: a 2-year follow-up.
    Mattos JL; Ferguson BJ; Lee S
    Int Forum Allergy Rhinol; 2015 Jun; 5(6):513-6. PubMed ID: 25845709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergen immunotherapy: an updated review of safety.
    James C; Bernstein DI
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):55-59. PubMed ID: 27906697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.
    Wasserman RL; Factor JM; Baker JW; Mansfield LE; Katz Y; Hague AR; Paul MM; Sugerman RW; Lee JO; Lester MR; Mendelson LM; Nacshon L; Levy MB; Goldberg MR; Elizur A
    J Allergy Clin Immunol Pract; 2014; 2(1):91-6. PubMed ID: 24565775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylaxis in the allergy practice.
    Leatherman BD
    Int Forum Allergy Rhinol; 2014 Sep; 4 Suppl 2():S60-5. PubMed ID: 25182358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaphylaxis: still a ghost behind allergen immunotherapy.
    Makatsori M; Calderon MA
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):316-22. PubMed ID: 24873937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adverse reactions to skin tests and immunotherapy in the practice of Mexican allergologists].
    Larenas Linnemann D; Rodríguez Pérez N; Becerril M
    Rev Alerg Mex; 2008; 55(2):62-70. PubMed ID: 19058483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety of immunotherapy and skin tests with allergens in children younger than five years].
    Rodríguez Pérez N; Ambriz Moreno Mde J
    Rev Alerg Mex; 2006; 53(2):47-51. PubMed ID: 16884027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of allergen immunotherapy: a literature review.
    Cook PR; Farias C
    Ear Nose Throat J; 1998 May; 77(5):378-9, 383-8. PubMed ID: 9615518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of home-based and office allergy immunotherapy: A multicenter prospective study.
    Hurst DS; Gordon BR; Fornadley JA; Hunsaker DH
    Otolaryngol Head Neck Surg; 1999 Nov; 121(5):553-61. PubMed ID: 10547469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse reactions associated with skin testing and immunotherapy.
    Lockey RF
    Allergy Proc; 1995; 16(6):293-6. PubMed ID: 8747313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trials investigating the role of allergen exposure in food allergy: where are we now?
    Metcalfe J; Prescott SL; Palmer DJ
    Curr Opin Allergy Clin Immunol; 2013 Jun; 13(3):296-305. PubMed ID: 23549151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Allergy Organization Systemic Allergic Reaction Grading System: Is a Modification Needed?
    Cox LS; Sanchez-Borges M; Lockey RF
    J Allergy Clin Immunol Pract; 2017; 5(1):58-62.e5. PubMed ID: 28065342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter real-world experience with epinephrine 0.5 mg dosing for anaphylaxis with allergen immunotherapy.
    Correa N; Quidwai A; Jeimy S; Rondilla N; White F; Moote W; Kuprowski M; Kim H
    Immunotherapy; 2021 Nov; 13(16):1325-1331. PubMed ID: 34612079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.
    Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P
    Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
    Moingeon P; Mascarell L
    Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergy immunotherapy for primary care physicians.
    Stokes JR; Casale TB
    Am J Med; 2006 Oct; 119(10):820-3. PubMed ID: 17000208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases].
    Malling HJ
    Wien Med Wochenschr; 1999; 149(14-15):410-4. PubMed ID: 10584284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful immunotherapy. A partnership between consultant and general practitioner.
    Katelaris CH
    Aust Fam Physician; 1998 Aug; 27(8):687-92. PubMed ID: 9735486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.